Literature DB >> 2650665

Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction.

W Robberecht1, J Bednarik, P Bourgeois, J van Hees, H Carton.   

Abstract

Chloroquine induced a myasthenic syndrome in a patient taking the drug for presumable reticular erythematous mucinosis. Clinical features and results of single-fiber electromyography were typical for a failure of neuromuscular transmission, while peripheral nerves and muscles were intact on clinical, biochemical, electrophysiologic, and pathologic investigation. The time course of the clinical and electrophysiologic findings during provocation with chloroquine and the absence of autoantibodies indicate that the syndrome was due to a direct effect of the drug on the neuromuscular junction. While not taking chloroquine, the patient showed a decremental response on a modified double-step nerve stimulation test and a mean consecutive difference on single-fiber electromyography that was at the upper limit of normal, indicating a subclinical impairment of neuromuscular transmission. These findings can explain the apparent rarity of the syndrome described, as a direct effect of chloroquine on the neuromuscular junction may only have clinical relevance in patients with a reduced neuromuscular safety factor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2650665     DOI: 10.1001/archneur.1989.00520400124033

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  9 in total

Review 1.  The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature.

Authors:  M Jallouli; D Saadoun; B Eymard; G Leroux; J Haroche; D Le Thi Huong; C De Gennes; C Chapelon; O Benveniste; B Wechsler; P Cacoub; Z Amoura; J C Piette; N Costedoat-Chalumeau
Journal:  J Neurol       Date:  2011-12-08       Impact factor: 4.849

2.  Hydroxychloroquine and Myasthenia Gravis-Can One Take This Risk?

Authors:  Arunmozhimaran Elavarasi; Vinay Goyal
Journal:  Ann Indian Acad Neurol       Date:  2020-06-10       Impact factor: 1.383

3.  Artesunate for severe acute Plasmodium falciparum infection in a patient with myasthenia gravis.

Authors:  Nathalie Dournon; Pierre Buffet; Eric Caumes; Bernard Clair; Stéphane Jauréguiberry
Journal:  Am J Trop Med Hyg       Date:  2012-07-23       Impact factor: 2.345

Review 4.  Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.

Authors:  S Christopher Jones; Alfred Sorbello; Robert M Boucher
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

5.  Chloroquine and Hydroxychloroquine Myopathy: Clinical Spectrum and Treatment Outcomes.

Authors:  Elie Naddaf; Pritikanta Paul; Omar F AbouEzzeddine
Journal:  Front Neurol       Date:  2021-02-02       Impact factor: 4.003

Review 6.  Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.

Authors:  Guillaume Hache; Jean Marc Rolain; Philippe Gautret; Jean-Claude Deharo; Philippe Brouqui; Didier Raoult; Stéphane Honoré
Journal:  Microb Drug Resist       Date:  2021-03       Impact factor: 3.431

7.  MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine.

Authors:  Shalini Bhaskar; Mohammed Fauzi Bin Abdul Rani
Journal:  Case Rep Med       Date:  2022-07-15

8.  Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib.

Authors:  David Sanford; Maria MacDonald; Michael Nicolle; Anargyros Xenocostas
Journal:  Hematol Rep       Date:  2014-06-19

9.  COVID-19-associated risks and effects in myasthenia gravis (CARE-MG).

Authors:  Srikanth Muppidi; Jeffrey T Guptill; Saiju Jacob; Yingkai Li; Maria E Farrugia; Amanda C Guidon; Jinny O Tavee; Henry Kaminski; James F Howard; Gary Cutter; Heinz Wiendl; Matthew B Maas; Isabel Illa; Renato Mantegazza; Hiroyuki Murai; Kimiaki Utsugisawa; Richard J Nowak
Journal:  Lancet Neurol       Date:  2020-12       Impact factor: 44.182

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.